|
|
Jerzy-Roch Nofer, Markus van der Giet, Markus Tölle, Iza Wolinska, Karin von Wnuck Lipinski, Hideo A. Baba, Uwe J. Tietge, Axel Gödecke, Isao Ishii, Burkhard Kleuser, Michael Schäfers, Manfred Fobker, Walter Zidek, Gerd Assmann, Jerold Chun, Bodo Levkau
J Clin Invest. 2004;
113(4):569
doi:10.1172/JCI18004
Abstract |
Full text
| PDF

H
DL is a major atheroprotective factor, but the mechanisms underlying this effect are still obscure. HDL binding to scavenger receptor-BI has been shown to activate eNOS, although the responsible HDL entities and signaling pathways have remained enigmatic. Here we show that HDL stimulates NO release in human endothelial cells and induces vasodilation in isolated aortae via intracellular Ca2+ mobilization and Akt-mediated eNOS phosphorylation. The vasoactive effects of HDL could be mimicked by three lysophospholipids present in HDL: sphingosylphosphorylcholine (SPC), sphingosine-1-phosphate (S1P), and lysosulfatide (LSF). All three elevated intracellular Ca2+ concentration and activated Akt and eNOS, which resulted in NO release and vasodilation. Deficiency of the lysophospholipid receptor S1P3 (also known as LPB3 and EDG3) abolished the vasodilatory effects of SPC, S1P, and LSF and reduced the effect of HDL by approximately 60%. In endothelial cells from S1P3-deficient mice, Akt phosphorylation and Ca2+ increase in response to HDL and lysophospholipids were severely reduced. In vivo, intra-arterial administration of HDL or lysophospholipids lowered mean arterial blood pressure in rats. In conclusion, we identify HDL as a carrier of bioactive lysophospholipids that regulate vascular tone via S1P3-mediated NO release. This mechanism may contribute to the vasoactive effect of HDL and represent a novel aspect of its antiatherogenic function.
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal.
Not all publishers participate in CrossRef, so this information is not comprehensive.
Additionally, data may not reflect the most current citations to this article,
and the data may differ from citation information available from other sources
(for example, Google Scholar, Web of Science, and Scopus).
Total citations by year
in CrossRef
Citations to this article
in CrossRef
(48)
| Title and authors |
Publication |
Year |
The beneficial effects of HDL-C on atherosclerosis: rationale and clinical results
Carlos G Santos-Gallego, Francisco Torres, Juan José Badimón
|
Clinical Lipidology
|
2011 |
The Impact of Bioactive Lipids on Cardiovascular Development
Alexander Kleger, Stefan Liebau, Qiong Lin, Götz von Wichert, Thomas Seufferlein
|
Stem Cells International
|
2011 |
Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M.
Christina Christoffersen, Hideru Obinata, Sunil B Kumaraswamy, Sylvain Galvani, Josefin Ahnström, Madhumati Sevvana, Claudia Egerer-Sieber, Yves A Muller, Timothy Hla, Lars B Nielsen, Björn Dahlbäck
|
Proc. Natl. Acad. Sci. U.S.A.
|
2011 |
Intravenous sphingosylphosphorylcholine protects ischemic and postischemic myocardial tissue in a mouse model of myocardial ischemia/reperfusion injury.
Christine Herzog, Martina Schmitz, Bodo Levkau, Ilka Herrgott, Jan Mersmann, Jan Larmann, Kai Johanning, Michael Winterhalter, Jerold Chun, Frank Ulrich Müller, Frank Echtermeyer, Reinhard Hildebrand, Gregor Theilmeier
|
Mediators of Inflammation
|
2010 |
Changing paradigm in HDL metabolism and cellular effects
Diederik F van Wijk, Erik SG Stroes, Houshang Monajemi
|
Clinical Lipidology
|
2009 |
Sphingosine-1-phosphate receptor signalling in the heart.
Christopher K Means, Joan Heller Brown
|
Cardiovascular Research
|
2009 |
Evidence for a role of sphingosine-1 phosphate in cardiovascular remodelling in Fabry disease
N. Brakch, O. Dormond, S. Bekri, D. Golshayan, M. Correvon, L. Mazzolai, B. Steinmann, F. Barbey
|
European Heart Journal
|
2009 |
Redox Control of Endothelial Function and Dysfunction: Molecular Mechanisms and Therapeutic Opportunities
Shane R. Thomas, Paul K. Witting, Grant R. Drummond
|
Antioxidants & Redox Signaling
|
2008 |
Sphingosine-1-phosphate as a mediator of high-density lipoprotein effects in cardiovascular protection
K. Sattler, B. Levkau
|
Cardiovascular Research
|
2008 |
Cholesterol efflux pathways and other potential mechanisms involved in the athero-protective effect of high density lipoproteins
A. R. Tall
|
Journal of Internal Medicine
|
2008 |
|